

Supplementary Table 3. Prognostic factors for progression-free survival

Progression-free survival	Univariable analysis			Multivariable analysis		
	HR	95% CI	P-value	HR	95% CI	P-value
Age, continuous (year)	0.99	0.98-1.00	0.027	1.00	0.99-1.01	0.616
ECOG PS, 0-1 vs. 2-4	4.77	2.87-7.95	<0.001	3.70	1.99-6.84	0.003
Gender, female vs. male	1.17	0.86-1.59	0.319			
Etiology, viral vs. non-viral	0.64	0.52-0.80	<0.001	0.84	0.64-1.09	0.180
mALBI, grade 1 vs. grade 2a	1.50	1.17-1.93	0.001	1.18	0.90-1.54	0.230
mALBI, grade 1 vs. grade 2b/3	2.99	2.35-3.81	<0.001	1.68	1.18-2.41	0.004
AFP, continuous	1.00	1.00-1.00	<0.001	1.00	1.00-1.00	0.017
PIVKA-II, continuous	1.00	1.00-1.00	<0.001	1.00	1.00-1.00	0.001
Child Pugh class, A vs. B	1.92	1.47-2.49	<0.001	0.76	0.52-1.09	0.138
Child Pugh class, A vs. C	16.84	9.09-31.22	<0.001	5.14	2.36-11.19	0.003
Presentation, solitary vs. multiple	2.40	1.93-2.99	<0.001	1.25	0.87-1.79	0.221
Presentation, solitary vs. diffuse	2.87	1.99-4.15	<0.001	1.07	0.69-1.67	0.758
Size, 5-10 vs. >10 (cm)	1.48	1.19-1.83	<0.001	1.00	0.97-1.04	0.821
Vascular invasion, negative vs. positive	1.25	0.94-1.64	0.119			
Biliary tract invasion, negative vs. positive	1.04	0.67-1.61	0.870			
PVTT classification, Vp0 vs. Vp1/2	1.42	1.05-1.92	0.022	0.97	0.66-1.44	0.894
PVTT classification, Vp0 vs. Vp3/4	2.65	2.12-3.33	<0.001	1.49	1.06-2.08	0.020
LN metastasis, negative vs. positive	1.91	1.49-2.46	<0.001	1.41	1.05-1.90	0.021
mUICC stage, stage II vs. III	2.17	1.58-2.98	<0.001	1.05	0.65-1.71	0.832
mUICC stage, stage II vs. IVA	4.06	2.95-5.60	<0.001	1.35	0.68-2.67	0.389
mUICC stage, stage II vs. IVB	3.79	2.73-5.28	<0.001	1.18	0.63-2.24	0.603
BCLC stage, A-B vs. C-D	2.80	2.19-3.57	<0.001	1.02	0.64-1.64	0.912
Treatment, sorafenib vs. BSC	2.41	1.66-3.49	<0.001	1.71	1.07-2.74	0.026
Treatment, sorafenib vs. surgery	0.23	0.16-0.33	<0.001	0.39	0.25-0.63	0.007
Treatment, sorafenib vs. other local treatments	0.99	0.76-1.30	0.94	1.27	0.94-1.72	0.120

The foreparts of the comma were set as the reference groups in the multivariable analysis.

HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; mALBI, modified albumin-bilirubin score; AFP, alpha-fetoprotein; PIVKA-II, protein induced by vitamin K absence-II; PVTT, portal vein tumor thrombosis; LN, lymph node; mUICC, modified International Union Against Cancer; BCLC, Barcelona Clinic Liver Cancer; BSC, best supportive care.